G
Gideon M. Blumenthal
Researcher at Food and Drug Administration
Publications - 137
Citations - 11084
Gideon M. Blumenthal is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Lung cancer & Clinical trial. The author has an hindex of 42, co-authored 136 publications receiving 8388 citations. Previous affiliations of Gideon M. Blumenthal include National Institutes of Health & Center for Drug Evaluation and Research.
Papers
More filters
Journal ArticleDOI
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
Journal ArticleDOI
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations
TL;DR: This review will provide an update on the clinical progress of various agents that target the PI3K/Akt/mTOR pathway and discuss strategies to combine these pathway inhibitors with conventional chemotherapy, radiotherapy, as well as newer targeted agents.
Journal ArticleDOI
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
TL;DR: StudyingPTEN in the continuum of rare syndromes, common cancers and mouse models provides insight into the role of PTEN in tumorigenesis and will inform targeted drug development.
Journal ArticleDOI
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
Dickran Kazandjian,Daniel L. Suzman,Gideon M. Blumenthal,Sirisha Mushti,Kun He,Meredith Libeg,Patricia Keegan,Richard Pazdur +7 more
TL;DR: Improved overall survival and objective response rates were demonstrated with nivolumab compared with docetaxel in the CheckMate 057 trial, an international, multicenter, open-label, randomized trial in patients with metastatic nonsquamous non-small cell lung cancer.
Journal ArticleDOI
PTEN hamartoma tumor syndromes
TL;DR: Improved understanding of the biology of PTEN and the PI3K/Akt/mTOR pathway means inhibitors of this pathway are being developed as anticancer agents and could have applications for patients with PHTS, for whom no medical options currently exist.